دورية أكاديمية
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer. Real-World Data from the RAMoss Study
| العنوان: | Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer. Real-World Data from the RAMoss Study |
|---|---|
| المؤلفون: | Di Bartolomeo, M., Niger, M., Tirino, G., Petrillo, A., Berenato, R., Laterza, M. M., Pietrantonio, F., Morano, F., Antista, M., Lonardi, S., Fornaro, L., Tamberi, S., Giommoni, E., Zaniboni, A., Rimassa, L., Tomasello, G., Sava, T., Spada, M., Latiano, T., Bittoni, A., Bertolini, A., Proserpio, I., Bencardino, K. B., Graziano, F., Beretta, G., Galdy, S., Ventriglia, J., Scagnoli, S., Spallanzani, A., Longarini, R., De Vita, F. |
| المساهمون: | Di Bartolomeo, M., Niger, M., Tirino, G., Petrillo, A., Berenato, R., Laterza, M. M., Pietrantonio, F., Morano, F., Antista, M., Lonardi, S., Fornaro, L., Tamberi, S., Giommoni, E., Zaniboni, A., Rimassa, L., Tomasello, G., Sava, T., Spada, M., Latiano, T., Bittoni, A., Bertolini, A., Proserpio, I., Bencardino, K. B., Graziano, F., Beretta, G., Galdy, S., Ventriglia, J., Scagnoli, S., Spallanzani, A., Longarini, R., De Vita, F. |
| بيانات النشر: | SPRINGER VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS |
| سنة النشر: | 2018 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: | adult, aged, 80 and over, antibodie, monoclonal, antibodies, humanized, female, human, male, middle aged, neoplasm metastasi, retrospective studie, stomach neoplasms |
| الوصف: | Ramucirumab-alone or combined with paclitaxel-represents one of the main options for patients failing first-line treatment for advanced gastric cancer.The RAMoss study aimed to evaluate the safety and efficacy profile of ramucirumab in the "real-life setting".Patients from 25 Italian hospitals started therapy consisting of ramucirumab 8 mg/kg i.v. d1,15q28 with or without paclitaxel 80 mg/m(2) i.v. d1,8,15q28. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).One hundred sixty-seven patients with disease progression on first-line therapy received ramucirumab as monotherapy (10%) or combined with paclitaxel (90%). Median treatment duration was 4 months (1-17 months). Global incidence of grade (G) 3-4 toxicity was 9.6%, and for neutropenia 5.4%; treatment was discontinued due to toxicity in 3% of patients. The most frequent adverse events (AE) were G1-2 fatigue (27.5%), G1-2 neuropathy (26.3%), and G1-2 neutropenia (14.9%). ORR was 20.2%. Stable disease was observed in 39.2% of patients, with a disease control rate of 59.4%. With a median follow-up of 11 months, median PFS was 4.3 months (95% confidence interval [CI] 4.1-4.7), whereas median OS was 8.0 months (95% CI: 7.09-8.9). In a multivariate analysis, ECOG performance status < 1 or ae1 (HR 1.13, 95% CI 1.0-1.27, p = 0.04) and the presence versus absence of peritoneal metastases (HR 1.57, 95% CI 1.63-2.39, p = 0.03) were independent poor prognostic factors.These "real-life" efficacy data on ramucirumab treatment are in line with previous randomized trials. Ramucirumab is well tolerated in daily clinical practice. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/29582224; info:eu-repo/semantics/altIdentifier/wos/WOS:000429367900009; volume:13; issue:2; firstpage:227; lastpage:234; numberofpages:8; journal:TARGETED ONCOLOGY; https://hdl.handle.net/11573/1657725Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85044459741 |
| DOI: | 10.1007/s11523-018-0562-5 |
| الإتاحة: | https://doi.org/10.1007/s11523-018-0562-5Test https://hdl.handle.net/11573/1657725Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.6F1177C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s11523-018-0562-5 |
|---|